![]() grew its holdings in shares of Outset Medical by 10.9% in the fourth quarter. now owns 4,491,145 shares of the company’s stock valued at $71,543,000 after purchasing an additional 146,881 shares during the period. grew its holdings in shares of Outset Medical by 3.4% in the third quarter. now owns 5,191,427 shares of the company’s stock valued at $77,144,000 after buying an additional 2,140,206 shares during the last quarter. raised its position in shares of Outset Medical by 70.1% in the second quarter. FMR LLC now owns 7,169,138 shares of the company’s stock valued at $106,533,000 after purchasing an additional 57,429 shares during the period. FMR LLC lifted its stake in shares of Outset Medical by 0.8% in the 2nd quarter. Several large investors have recently modified their holdings of OM. Corporate insiders own 4.00% of the company’s stock. Insiders sold 147,263 shares of company stock valued at $3,650,017 in the last three months. The disclosure for this sale can be found here. Following the sale, the general counsel now owns 66,422 shares of the company’s stock, valued at approximately $1,618,039.92. The shares were sold at an average price of $24.36, for a total transaction of $33,080.88. Brottem sold 1,358 shares of Outset Medical stock in a transaction dated Thursday, February 16th. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Following the completion of the transaction, the chief executive officer now directly owns 290,243 shares of the company’s stock, valued at approximately $6,051,566.55. The shares were sold at an average price of $20.85, for a total transaction of $625,500.00. In related news, CEO Leslie Trigg sold 30,000 shares of Outset Medical stock in a transaction dated Thursday, December 1st. ![]() ![]() ![]() During the same period last year, the firm earned ($0.87) EPS. Outset Medical had a negative net margin of 141.24% and a negative return on equity of 55.22%. The firm had revenue of $32.01 million for the quarter, compared to the consensus estimate of $31.51 million. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.02. Outset Medical ( NASDAQ:OM – Get Rating) last announced its quarterly earnings data on Monday, February 13th. The company has a debt-to-equity ratio of 0.39, a current ratio of 7.19 and a quick ratio of 5.13. The company’s fifty day moving average price is $26.66 and its 200-day moving average price is $20.78. Outset Medical has a one year low of $11.41 and a one year high of $48.71. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -7.50 and a beta of 1.50. Shares of OM stock opened at $25.57 on Friday. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.50. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Finally, Cowen cut their target price on shares of Outset Medical from $33.00 to $22.00 in a research note on Wednesday, November 9th. The Goldman Sachs Group cut their target price on shares of Outset Medical from $34.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday, November 9th. Morgan Stanley raised their target price on shares of Outset Medical from $17.00 to $27.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. Cowen cut their target price on shares of Outset Medical to $22.00 in a research note on Tuesday, November 15th. They set an “outperform” rating and a $23.00 price objective on the stock. Royal Bank of Canada began coverage on shares of Outset Medical in a research report on Friday, November 11th. ![]() Several other analysts also recently commented on the stock. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |